Argenx Se (ARGX) Operating Income Growth (5y) (2021 - 2026)

Argenx Se (ARGX) Operating Income Growth (5y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 14.87%
Dec 31, 2025 36.20%
Sep 30, 2025 37.51%
Jun 30, 2025 21.18%
Mar 31, 2025 27.01%
Dec 31, 2024 18.43%
Sep 30, 2024 -39.54%
Jun 30, 2024 3.53%
Mar 31, 2024 -68.56%
Dec 31, 2023 -28.57%
Sep 30, 2023 -25.91%
Jun 30, 2023 -50.06%
Mar 31, 2023 -42.95%
Dec 31, 2022 -21.69%
Sep 30, 2022 -60.87%
Jun 30, 2022 -150.49%
Mar 31, 2022 -90.21%
Dec 31, 2021 -89.10%